BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...begin repair processes. FDA is reviewing an expanded access IND for CAP-1002 to treat COVID-19. Revive Therapeutics...
BioCentury | Aug 22, 2016
Financial News

Revive Therapeutics completes private placement of units

Revive Therapeutics Ltd. (TSX-V:RVV; OTCQB:RVVTF), Vaughan, Ontario Business: Neurology, Autoimmune, Endocrine/Metabolic Date completed: 2016-08-18 Type: Private placement of units Raised: C$1.5 million ($1.2 million) Units: 15 million Price: C$0.10 (unit) Shares after offering: 47.4 million...
BioCentury | Jun 27, 2016
Financial News

Revive Therapeutics completes rights offering of units

Revive Therapeutics Ltd. (TSX-V:RVV; OTCQB:RVVTF), Vaughan, Ontario Business: Neurology, Autoimmune, Endocrine/Metabolic Date completed: 2016-06-20 Type: Rights offering of units Raised: C$844,693 ($657,931) Shares: 8.4 million Price: C$0.10 (unit) Shares after offering: 32.4 million Investor: Existing...
BioCentury | Jun 6, 2016
Financial News

Revive Therapeutics proposes private placement of units

Revive Therapeutics Ltd. (TSX-V:RVV; OTCQB:RVVTF), Vaughan, Ontario Business: Neurology, Inflammation Date announced: 2016-05-30 Type: Private placement of units To be raised: Up to C$1.5 million ($1.1 million) Units: 15 million Price: C$0.10 (unit) Shares outstanding...
BioCentury | Jun 6, 2016
Financial News

Revive Therapeutics proposes rights offering of units

Revive Therapeutics Ltd. (TSX-V:RVV; OTCQB:RVVTF), Vaughan, Ontario Business: Neurology, Inflammation Date announced: 2016-05-16 Type: Rights offering of units To be raised: Up to C$2.4 million ($1.8 million) Shares: 23.9 million Price: C$0.10 (unit) Shares outstanding...
BioCentury | Nov 12, 2015
Distillery Techniques

Techniques: Transgenic ionotropic glutamate receptor kainate 4 (GRIK4)-expressing mouse model of autism spectrum disorder (ASD)

...and social interaction deficits that were not observed in normal mice. In the transgenic model, tianeptine...
BioCentury | Oct 5, 2015
Clinical News

Bucillamine: Interim Phase IIa data

...oral colchicine. No treatment-related serious adverse events were reported. The trial is enrolling 66 patients. Revive Therapeutics...
BioCentury | May 11, 2015
Clinical News

Revive Therapeutics preclinical data

...generic approved as an anti-depressant in Asia and Europe. Revive Therapeutics Ltd. (TSX-V:RVV), Vaughan, Ontario Product: Tianeptine...
BioCentury | Dec 22, 2014
Financial News

Revive Therapeutics completes private placement of units

Revive Therapeutics Ltd. (TSX-V:RVV), Vaughan, Ontario Business: Neurology, Inflammation Date completed: 2014-12-18 Type: Private placement of units Raised: C$3 million ($2.6 million) Units: 5 million Price: C$0.60 (unit) Shares after offering: 23.9 million Underwriter: Beacon...
BioCentury | Dec 8, 2014
Clinical News

Bucillamine: Phase IIa start

...At year end, Revive Therapeutics will begin an open-label, U.S. Phase IIa trial to evaluate a high...
...once-daily oral REV-002 in combination with low-dose colchicine for 7 days in about 66 patients. Revive Therapeutics...
Items per page:
1 - 10 of 17